David Band To Step Down From Pacific Edge Board

Pacific Edge Limited (NZX:PEB) advises that long serving Director, David Band, has indicated that he will step down from the Board at the upcoming Annual Meeting, to be held in August 2018.

David was appointed to the Board in 2007 and has held the position of Deputy Chair for most of his tenure. He has also been a member of a number of the Company’s subsidiary Boards and advisory committees.

Chair of Pacific Edge, Chris Gallaher, said: “David has made a significant contribution to Pacific Edge as the Company has developed its unique molecular diagnostic technology and embarked on its commercial journey. His experience in the life sciences sector, and expertise in corporate governance, talent management and commercialisation of innovation have been a key factor in Pacific Edge’s successful evolution from R&D to commercial reality.”

David said: “It has been a privilege to have been able to contribute to the development and launch of Cxbladder, a diagnostic test that enables better care, better clinical decision making and better use of  healthcare resources. As the Company moves ever close to commercial success, I believe it is now time to step down and allow for fresh thinking and skills to take the Company forward.”

Pacific Edge will take the opportunity to acknowledge David’s contributions at the Annual Shareholders Meeting.

The Board has a process underway to identify and appoint a new Director.

ENDS

For more information contact:

David Darling

Chief Executive Officer

Pacific Edge Ltd

P: +64 (3) 479 5800